Nanobiotix raises €86.1 million, presents updated NBTXR3 data in Q1 2026 update
Biotechnology company Nanobiotix reported first quarter 2026 financial results. The company raised approximately €86.1 million from a May follow-on offering and presented new data on its cancer therapy NBTXR3.
Paris and Cambridge, Mass. – Nanobiotix, a late-stage clinical biotechnology company, provided an update on its operational progress and financial results for the first quarter of 2026. The company announced it completed a follow-on offering in May 2026, raising approximately €86.1 million in gross proceeds to support platform development.
Key operational highlights included the presentation of new data from Part 1 of the Phase 2 CONVERGE study, which evaluates NBTXR3 for patients with inoperable stage 3 non-small cell lung cancer (NSCLC). Presented at the 2026 European Society for Radiotherapy and Oncology (ESTRO) annual meeting, the data showed an overall response rate of 85.7% and a complete response rate of 57.1% in a cohort of seven patients receiving NBTXR3 with chemoradiotherapy and durvalumab consolidation.
Nanobiotix also reported acceptance by the FDA of a protocol amendment to the ongoing pivotal NANORAY-312 study. This amendment eliminates the planned interim analysis and modifies the final analysis to be conducted sooner with fewer events. The company also presented new preclinical data on its Nanoprimer platform, which showed potential to enhance systemic delivery and reduce toxicity of lipid nanoparticle-delivered DNA for immunotherapy.
Financially, Nanobiotix reported €42.1 million in cash and cash equivalents as of March 31, 2026. The company stated that combined with the proceeds from the recent offering, this is expected to be sufficient to fund operations into 2029.